Surgical oncology: Cancer risk reduction in BRCA mutation carriers.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Restoration of TFPI2 by LSD1 inhibition suppresses tumor progression and potentiates antitumor immunity in breast cancer.Cancer letters · 2024
   Article
2. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.Cancers · 2024
   Review
3. Molecular and clinical oncology · 2021
   Article
4. Association BetweenFrontiers in pharmacology · 2018
   Article
5. Clinical implications for BRCA gene mutation in breast cancer.Molecular biology reports · 2012
   Article
6. The Role of Irisin and Physical Activity in Breast Cancer.In vivo (Athens, Greece)
   Review

Corrections and comments

• Comment on
  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.